MOCS Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Making Obstetrics Care Smart (MOCS) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
MOCS Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Michael Rein | AFFOA | michael@affoa.org | Bedford, MA | AFFOA pioneers advanced fiber and textile technologies that integrate sensors, electronics, and data networks into textile based wearable systems. Efforts focus on scalable manufacturing of smart fabrics for physiological monitoring, including seamless integration of biosensors for real-time data capture for continuous health monitoring. Our capabilities focus on sensor integration, electronics development, system integration and producing deployable prototypes to be used in field environment. | AFFOA seeks partners with expertise in biomedical sensing, obstetric device development, clinical validation, and data analytics. We are happy to partner with any organization that is interested in developing a wearable textile based product to solve MOCS program challenges. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Kasie Bailey | Truveta | kasieb@truveta.com | Seattle, WA | Truveta has over 130 million EHR RWD for RWE. This also includes over 1 million mother-child deterministic linkages that have at least 6 years of longitudinal history. Available in real time and research ready. | Innovative partners who have a solution that needs RWD/RWE. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Peter Washington | University of California, San Francisco (UCSF) | peter.washington@ucsf.edu | San Francisco, CA | Dr. Washington's research lab, the UCSF TECH Lab, builds digital diagnostics and interventions using AI applied to devices such as wearables. In particular, Dr. Washington is the PI of an NSF Smart and Connected Health (SCH) grant on predicting repeat adverse health events (e.g., blood pressure spikes) from wearable biosignals read from consumer and resesarch-grade devices. This work is directly in line with the goals of MOCS: continuously monitoring the placenta using non-invasive wearable AI. | Dr. Washington is aiming to partner with team members with expertise on the hardware/sensor development side. Dr. Washington is happy to parter with clinical experts as well. Additionally, Dr. Washington has existing connections with the OBGYN clinics at UCSF (for a separate project), and has established pipelines for both EHR and community recruitment services through UCSF Health. We can loop in these partners as well. | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Conor Walsh | Harvard Move Lab | walsh@seas.harvard.edu | Boston, MA | Wearable sensing including wearable ultrasound, fNIRs. Human centric design, software, UX/UI, human factors. | Clinical partners and experts to help set requirements for hardware. Experts in signal processing. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Ashkan Afshin | Novelna Inc. | ashkan@novelna.com | Palo Alto, CA | Novelna develops proteomics- and AI-driven diagnostics for early disease detection. Our research focuses on biomarker discovery, multi-protein panel design, rapid immunoassay development, and point-of-care test integration. We also conduct analytical validation and multi-site clinical studies to support reliable, low-cost diagnostics in diverse care settings. | We seek strong, execution-focused partners able to complement our diagnostic and biomarker capabilities. We prioritize groups with proven reliability, strong technical or clinical capabilities, and the ability to accelerate development, validation, and deployment in real-world settings. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Farah Deeba | University of North Carolina at Charlotte | fdeeba@charlotte.edu | Charlotte, NC | Quantitative Ultrasound for Fetal Hypoxia Prediction | Clinical Partner; Ultrasound Companies; | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Soheil Ghiasi | University of California, Davis | ghiasi@ucdavis.edu | Davis, CA | My research team has been working to develop an non-invasive sensor system for intrapartum measurement of fetal blood oxygen saturation and fetal blood pH. | Looking for 1) malpratice attorneys who specialize in obstetrics, and 2) those with expertise in "wearable ultrasound" systems. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Eliel Oliveira | Connxus | eliel@connxus.org | Austin, TX | Maternal health support in remote areas through the analysis of geographical distance impediments and the usage of remote monitoring solutions to improve maternal outcomes. | Organizations that need clinical data access in real-time and in clinical settings to support the speedy implementation of innovative solutions for maternal health outcomes improvement | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Karen Becker | GE HealthCare Maternal Infant Care | KarenStarr.Becker@gehealthcare.com | Waukesha, WI | Perinatal Solutions- Sensors to Insights | 1- Clinicians that understand the complexity of fetal to newborn transition to extrauterine life and signs of stress 2- Early clinical adopters that will champion early concepts to move to actionable clinical decision designs | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Jenn Hadlock | Institute for Systems Biology | jhadlock@isbscience.org | Seattle, WA | Model development for explainable, trustworthy clinical decision support. We currently work on electronic health records wth over 1,000,000 maternal-neonatal dyads across six states. | Longitudinal data from novel biomedical observations, beyond what is currently captured in standard of care. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Kanchana Devanathan | Vanderbilt University | kanchana.devanathan@vanderbilt.edu | Nashville, TN | Biophotonics, Biomedical Optics, Medical Image Analysis, Computational Intelligence | Clinical Collaboration, Cohort Recruitment | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Jundong Li | University of Virginia | jundong@virginia.edu | Charlottesville, VA | AI, Machine Learning, and Data Science | I am looking for teams that need my expertise in AI/ML/data science | Collaborator, Collaborator |
| Justin Chan | Carnegie Mellon University | justinchan@cmu.edu | Pittsburgh, PA | Contactless health sensing systems | Medical expertise | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Anand Muthusamy | Convergent Research | anand@convergentresearch.org | Los Angeles, CA | Continuous molecular monitoring; multi-modal physiological measurements and quantitative modeling; protein engineering; biomarker validation. | Clinical collaborators; clinical workflow and integration rails | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Thomas Berti | Planned System International | Tberti@plan-sys.com | Arlington, VA | PSI provides mission-critical digital infrastructure and AI solutions for the life sciences and healthcare sectors to the Federal Government. Our core expertise lies in developing integrated platforms for advanced data management, computational analytics, automated and compliant manufacturing. We also own and operate a light weight Electronic Health Record (EHR) application, giving us unparalleled insight into clinical trial management, device communication and regulatory pathways. | PSI is uniquely positioned to serve as a central data and technology partner for a MOCS consortium. We offer end-to-end support for a project's digital needs. Moreover, we have experience developing ARPA-H proposals as well working with ARPA-H on programs we've both won as a prime and sub. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Cassidy Cantin | Latham BioPharm Group | ccantin@lathambiopharm.com | Elkridge, MD | Sia/LBG provides full-spectrum support for federal funding, specializing in proposal development and post-award execution. Our subject matter experts in digital health bring deep domain knowledge in areas like health IT, AI-driven diagnostics, and data interoperability. We craft compliant, compelling proposals tailored to funder priorities and guide post-award reporting, stakeholder engagement, and program delivery to ensure lasting success. | We bring 20+ years of USG funding expertise, with deep capabilities in post-award support, compliance, financial reporting, and product/program management. Our digital health SMEs offer specialized insight in telehealth, AI diagnostics, and data interoperability. We’re looking to join a team that values strategic execution, cross-functional collaboration, and is ready to engage ARPA-H with clarity, agility, and shared purpose. | Collaborator, Collaborator |
| Abhinav Bhushan | Illinois Institute of Technology | abhushan@iit.edu | Chicago, IL | wearable devices, microfluidics, IoT, AI | clinicians | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Simon Evans | Phenome Health | simon.evans@phenomehealth.org | Seattle, WA | Phenome Health has expertise in machine learning and AI as applied to multi-dimensional health data, including multiomics, wearable signals, etc. in predicting health trajectories. | Phenome Health would seek partners with emerging technologies to capture non-invasive digital signals and/or low invasive biological signals as inputs to our analysis platform. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Chen Chen | University of Virginia | zrh6du@virginia.edu | Charlottesville, VA | My research focuses on developing trustworthy and efficient machine learning methods for complex networked systems, with applications in health informatics, computational epidemiology, and infrastructure analytics. My expertise lies in graph machine learning, data-driven optimization, and AI-based modeling for large-scale interconnected systems and real-world applications to advance data science and artificial intelligence. | We are looking for teaming partners with expertise in maternal health, clinical obstetrics, biomedical sensing, or digital health technology. Ideal collaborators include clinicians and practitioners developing AI-driven monitoring, predictive modeling, and decision-support tools to improve maternal and neonatal outcomes through intelligent, data-informed obstetric care systems. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Gilles Clermont | NOMA AI, Inc. | g.clermont@noma.ai | Pittsburgh, PA | Risk stratification for post-partum hemorrhage; emergency triage solution; machine learning & AI; time series & continuous signals | Device manufacturers that could provide raw fetal heart rate data | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Sahil Shah | University of Maryland, College Park | sshah389@umd.edu | College Park, MD | Our lab develop integrated IC for pH measurement and wireless transmission with on-chip AI. | Packaging,Biomedical, clinical. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Kelsey Buhr | GE HealthCare | kelsey.buhr@gehealthcare.com | Waukesha, Wisconsin, WI | Our Maternal Infant Care team is advancing innovations in maternal-fetal monitoring. Our goal is to combine clinical accuracy with user-centered design, ensuring that technology improves the care experience and outcomes for both patients and clinicians by: - Enabling mobility during labor without compromising monitoring quality. - Reimagining fetal oximetry parameter for deeper insights into fetal well-being. - Delivering predictive insights and decision-support tools that drive better outcomes. | We seek partners who bring complementary expertise, innovative technologies, and a shared mission. Ideal collaborators value co-creation to deliver user-centered, evidence-based innovations and include clinical researchers/ experts, advanced and/or novel technologists, and/or other like minded experts. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Rachel Gerver | Triple Ring Technologies | rgerver@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech and life sciences. Our interdisciplinary team, including many PhDs, excels in advancing technologies to FDA approval while collaborating with academics and commercial entities. We are currently engaged with ARPA-H on a number of programs. We offer services for device/system development and have direct experience in diagnostics, monitoring systems, and AI/ML algorithms. We are ISO 13485 certified. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our collaborative assistance to design enabling devices and technologies while navigating the FDA regulatory pathway. We have acted as prime, subcontractor, or vendor on previous submissions. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Xueding Wang | University of Michigan | xdwang@umich.edu | Ann Arbor, MI | We are focusing on development and clinical applications of advanced light and/or ultrasound based non-invasive imaging/monitoring devices. | We are a team with expertise in medical imaging, photonics, electrical engineering, and pediatric cardiology, but we are open for potential collaborations with others to best address the targeted clinical problems. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Allen Olson-Urtecho | Studio Bahia | allen@studiobahia.org | San Antonio, TX | Studio Bahía builds accessible VR and AI therapies used in U.S. hospitals and low-resource settings. Our work spans pain, anxiety, and trauma care (Lili VR; Rubi AI VR EMDR) and developing maternal VR training with UNICEF Congo. We designed a mobile-powered maternal–fetal sensors measuring FHR, MHR, BP, and EEG with onboard AI for real-time fetal assessment, designed as a next-generation, low-cost fetal monitor. | We seek hospitals, maternal health networks, researchers, and implementation partners to pilot, clinically validate, and scale our maternal–fetal sensor and AI app. Ideal partners can support multi-site trials, intrapartum testing, and integration into existing labor and delivery workflows. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Emerson Keenan | Kali Healthcare | emerson@kalihealthcare.com | Melbourne, Australia | Kali Healthcare specializes in wearable technology and AI diagnostics for pregnancy monitoring. Our research focuses on non-invasive fetal ECG technology to provide continuous monitoring of maternal, fetal and uterine activity, as well as developing clinically interpretable AI algorithms to better identify fetal hypoxia. We have developed a mature sensor-to-cloud technology stack for in-clinic and remote monitoring, and have deep clinical and technical expertise to support novel research goals. | We seek US-based clinical groups, and established MedTech partners to complement our technology capabilities. We are looking for collaborators with clinical and/or commercial expertise to co-design and validate user-centered applications and integrations of our technology platform. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Yishai Sompolinsky | Hadassah Hebrew University medical center | Ysompo@gmail.com | Jerusalem Israel | The Labor-AI Lab at Hadassah -HUJI conducts research applying machine learning to obstetrics, including validated models for VBAC prediction, real-time labor outcome forecasting, severe neonatal outcome prediction, and nationwide maternal–infant epidemiology. Our work integrates clinical and imaging data to generate robust, peer-reviewed insights that advance maternal and fetal care | We seek partners with complementary strengths in large-scale maternal health research, clinical data infrastructure, implementation science, and biomedical engineering. Ideal collaborators include U.S.-based academic centers or industry groups with capabilities in advanced analytics, digital health deployment, and multicenter clinical evaluation of obstetric innovations. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Liping Feng | Duke University | feng0007@mc.duke.edu | Durham, NC | We have expertise in device development and maternal fetal medicine and reproductive science | MFM expertise | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Steve Falk | GE HealthCare | steven.falk@gehealthcare.com | Waukesha, WI | Perinatal Product Development | Developing sensors to insights in the Labor, Delivery, and Newborn Care space | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Mark Evans | KLS LLC | Evans@CompreGen.com | Las Vegas, NV | Our focus is from the start of labor through the 1st hour postpartum using our new methodology for the interpretation of EFM, incorporating contextualization of its interpretation using maternal, obstetrical and fetal risk factors and increased uterine activity. We have shown considerably improved and earlier detection of risk. We have 19 refereed publications and 20 patents. We are currently finishing our platform for widespread testing including a wearable device for postpartum monitoring. | Hospital organizations having urban and rural high and low risk patients, medical device manufacturing companies. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Leal Segura | Mayo Clinic Rochester | segura.leal@mayo.edu | Rochester, MN | Our multidisciplinary team brings decades of experience in perinatal outcomes, embedded signal processing, and autonomous physiologic sensing systems delivering real-time feedback. We have engineered a monitor that captures high-fidelity fetal physiologic waveforms during active labor and wirelessly summarizes the fetal status on a point-of-care device. In parallel, we are advancing ML/AI algorithms for early detection of fetal acidosis and cardiovascular decompensation during labor. | Our strength is in scientific innovation, rapid prototyping and clinical translation of next-generation physiologic monitors. We seek partners who can help accelerate our innovation toward ARPA-H scale impact: (1) those with expertise in navigating FDA pathways for fetal applications and manufacturing capabilities, and (2) nationwide clinical partners capable of supporting large, multi-site device evaluation across broad settings, from high volume academic centers to maternity care deserts. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Andrew Omidvar | Philips | andrew.omidvar@philips.com | Amsterdam, Cambridge, MA | AI for medical devices to lower the skills needed to operate them in low resources setting. We have extensive capabilities in FM, stratification of pregnancy risk with AI. We have a long lasting reach in imaging, PET, CT, Xray , ultrasound and MR. We have a dominant market share in patient monitoring. We have extensive experience with quality, patient safety and regulatory regimes in US and globally. | We are looking for medical schools and providers in low resources setting to conduct clinical studies and clinical validation. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Omer Inan | Georgia Tech | omer.inan@ece.gatech.edu | Atlanta, GA | Wearable non-invasive sensing of cardiopulmonary parameters, including seismocardiogram (SCG) based hemodynamics, wearable reflectance based photoplethysmogram (PPG) for capturing vascular information and pulse oximetry, and bioimpedance based determination of internal fluid status and breathing mechanics. | We are looking to partner with other organizations that have expertise in different sensing modalities, and in particular with groups that have interest in TA1. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| KEVIN BUSTO | Vega Technology Group LLC | kbusto@vegatcgroup.com | North Canton, OH | Application Engineer in Shortwave Infrared Imaging and Wireless Communication. flexible Antenna Development, Build. Build design with, www.emberion.com and www.blues.com | Clinical Research and Development, Software development and Hardware in AI, Understanding of Imaging technology, | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Penny Flicker | Baymatob | penny.flicker@baymatob.com | Sydney, Australia | Wearable sensors, maternal and fetal health, AI/ML, remote-monitoring, in-hospital monitoring. Baymatob has developed a patent-protected non-invasive wearable sensor and maternal and fetal monitoring system enabled by machine learning algorithms. This system is being developed to reduce the prevalence and severity of complications in pregnancy and labor. | We are based in Sydney, Australia and are seeking US-based partners with existing relationships with healthcare systems and providers as well as clinical partners with advanced expertise in fetal hypoxia. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Rebecca Harston | Thermo Fisher Scientific | rebecca.harston@thermofisher.com | Wilmington, NC | PPD, the clinical research business of Thermo Fisher Scientific, provides full regulatory, clinical trial execution, and lifecycle support for devices and diagnostics, including the full life cycle: feasibility, pilot, pivotal, post-approval/registry with a global footprint. We support women's health indications with patient-centered methods to increase representation and reduce participation barriers. PPD's expertise includes a Pregnancy & Lactation Center of Excellence. | We are seeking technology partners in either TA1 or TA2 that require expertise in maternal and fetal health, diagnostic/device regulatory expertise, and global clinical capabilities. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Mark Samuels | DiligentCXO | Msamuels@diligentcxo.com | Atlanta, GA | Extensive experience with wireless electronic fetal monitoring systems and non-invasive optical spectroscopy and AI enabled BCG for vital signs monitoring. | Teams are organizations with complementary technology or capabilities | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Amrish Nair | Biorithm | amrish@bio-rithm.com | Singapore | Wearable fetal ECG monitors and algorithms for detecting fetal distress. | Clinical partners for co development and validation. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Junjie Yao | Duke University | jy211@duke.edu | Durham, NC | Photoacoustic and ultrasound imaging of placental and fetal perfusion and oxygenation | OB/GYN clinical practitioners and legal experts on the patient/hospital law | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Rachel Cummings | Columbia University | rac2239@columbia.edu | New York, NY | My expertise focuses on privacy-preserving machine learning (PPML), specifically differential privacy. I work on algorithm design for PPML and learning theory, as well as on sociotechnical challenges of deploying new technologies, including communication to non-technical stakeholders, and other human-computer interaction aspects. I recently experienced a late-stage pregnancy loss and am motivated to shift my research to this area, even if it is slightly outside of my previous research area. | I do not plan on leading a submission, but rather I am looking to join a team where my expertise can be valuable. | Collaborator |
| Helen Cooksley | University College London | h.cooksley@ucl.ac.uk | London, United Kingdom | At the Elizabeth Garret Anderson Institute for Women's Health, we bring together multidisciplinary clinicians and researchers to make a real and sustainable difference to women's and babies health. From birth to puberty, motherhood to menopause, maturity to old age, the lifecourse of women around the world is filled with opportunities to improve health and well being. | open to all opportunities | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Carolyn Bayer | Tulane University | carolynb@tulane.edu | New Orleans, LA | Our research laboratory has developed spectral photoacoustic imaging for in vivo monitoring of placental oxygenation. We have devised strategies for translating this imaging technology to the clinic. | AI/ML image analysis expertise would help improve diagnostic specificity and sensitivity. Research clinical expertise would help ensure accurate interpretation of our imaging results. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Fred Miller | Arbor Research Collaborative for Health | fred.miller@arborresearch.org | Ann Arbor, MI | Arbor Research is a national leader in data-driven healthcare improvement, specializing in clinical research, predictive analytics, and multi-site quality initiatives. We advance biomarker validation, risk modeling, and point-of-care diagnostics with strong regulatory and data systems. We support clinical quality initiatives in maternal health via data collection and implementation to improve outcomes and reduce unnecessary interventions. | Arbor Research seeks partners with biomarker and assay development expertise, including labs or diagnostics firms able to identify fetal hypoxia biomarkers and prototype point-of-care tests. We also need urban, rural, and birth-center clinical sites, plus partners for FDA strategy, QMS, human-factors engineering, and commercialization, reimbursement, and manufacturing planning. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Duarte Dias | INESC TEC | duarte.f.dias@inesctec.pt | Porto, Portugal | INESC TEC is a private, non-profit research and development institution in Portugal focused on systems and computer engineering, technology, and science, with research spanning artificial intelligence, robotics, and bioengineering. C-BER (Biomedical Engineering Research Center) is one of its research centers, specializing in creating health technology for screening, diagnosis and follow-up through interdisciplinary work in areas like BioInstrumentation, Biomedical Imaging, and NeuroEngineering. | C-BER focus on wearable textile, signal processing and AI, with e-health applications for clinical tests and validation of the algorithms. To complement our expertise we would need to team up with clinical knowledge entities that can support us to collect more data and validate our technology. A company ready to embrace the project and start a product roadmap and future adoption of the technology would also be key for us, since our focus is on research-based technology R&D. | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Brock Polnaszek | Medical College of Wisconsin | bpolnaszek@mcw.edu | Milwaukee, WI | As one of 12 NIH Maternity Health Research Center of Excellence in the United States, a part of our research is examining prospectively novel intervention on labor and delivery to reduce perinatal morbidity/mortality. | We are looking for the technological and artificial intelligence based experts as we lead the clinical investigation portion of the device. | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Oscar Gleeson | CergenX | Ogleeson@cergenx.com | Cork, Ireland | Develops AI-driven solutions for neonatal and maternity care. Spun out from the INFANT Centre for Maternal & Child Health Research, CergenX built a proprietary AI platform that transforms complex physiological data into real-time, expert-level insights. Our first product, an FDA Breakthrough Device, delivers rapid, AI-driven assessments of newborn brain function without specialist expertise, converting EEG data into simple, actionable results for the first scalable, objective brain assessment. | CergenX is looking to partner with hardware manufacturers experienced in fetal heart-rate monitoring and wireless technologies, as well as U.S. Health Systems. Leveraging our unique AI platform, decades of research, and a technical team with a proven track record of bringing AI-driven clinical decision support products from concept through regulatory clearance, we are excited to collaborate on the development of novel solutions. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Eric Dy | Bloomlife | eric@bloomlife.com | San Francisco, CA | Bloomlife has a background in developing advanced patch based medical devices to measure maternal and fetal physiology in both antepartum and intrapartum setting. We also have experience developing signal processing algorithms for extracting clinically relevant features from electrophysiological signals and AI/ML background for combining features towards digital biomarkers. | We are looking for clinical collaborators with experience in fetal EKG and fetal diagnosis. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Guan Xu | University of Michigan | guanx@umich.edu | Ann Arbor, MI | My research focuses on abdominal photoacoustic imaging, including transcutaneous approach and endoscopic approach with miniaturized sensors. | Currently we have clinicians, engineers in imaging and sensor development in our team. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Jun Xia | University at Buffalo | junxia@buffalo.edu | Buffalo, NY | Development of ultrasonic and photoacoustic devices for clinical imaging applications. | Academic and industrial partners in device miniaturization and regulatory pathways. Clinical and preclinical collaborators in device validation. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Eric Dy | Bloomlife | eric@bloomlife.com | San Francisco, CA | Bloomlife is developing a next-generation maternal–fetal monitoring platform based on high-fidelity abdominal electrophysiology, including fetal ECG, maternal ECG, and uterine electromyography. Our system provides: • Continuous, non-invasive, wireless monitoring, • Precise beat-to-beat fetal ECG data, • Superior contraction sensing via uterine EMG, • A data science infrastructure for machine-learning interpretation, • Experience delivering FDA-regulated maternal monitoring solutions. | We are actively seeking clinical partners across diverse care environments to meet the MOCS program’s engagement requirements. Participating sites will help shape a new standard of fetal monitoring by providing feedback, supporting early studies, and contributing to the evidence base needed to transform care nationally. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Janna Morrison | UniSA | janna.morrison@unisa.edu.au | Adelaide, South Australia, Australia | Expertise in developing large animal models of fetal hypoxia with physiological monitoring including fetal blood gases, blood pressure/heart rate, hormones and MRI of the placenta and fetal cardiac function. Expertise in neonatal ventilation studies in large animal models. Expertise in molecular analysis of tissue responses to fetal hypoxia. Access to GLP facilities. Ability to perform human trials. | Multi-site opportunities. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Robert Froemke | NYU Grossman School of Medicine | robert.froemke@med.nyu.edu | New York City, NY | We perform 24/7 multi-camera and sensor monitoring of gestation, labor, and post-partum care in animal models (mostly mouse family life), combined with long-term continuous physiological measurements | Human subjects/clinical researchers | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Gari Clifford | Emory University | gari@ieee.org | Atlanta, GA | Focusing on AI-driven systems for fetal & maternal monitoring and modeling, integrating low-cost sensors, Doppler, & ECG to predict complications during labor. Our work uses deep learning for real-time maternal-fetal signal analysis, multimodal data fusion, & edge-compute mHealth platforms to support clinicians and improve outcomes. With applications in fetal development, hypoxia, & fetal activity, from the 2nd trimester onwards, we have extensive experience in translation & regulation. | We are looking for partners that can provide near-infrared spectroscopy of the placenta for abdominal monitoring fetal oxygenation, and expertise in ultrasound sensor development, miniaturization of a reduced-lead noninvasive fetal ECG monitor for portable wireless use. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Tzali Cnaani | Carmel Diagnostics | tzali@carmel-diagnostics.com | 9a barlev st. Kiryat-tivon, 3608267, ISRAEL | Carmel Diagnostics is an innovative SME specializing in advanced biomedical diagnostics based on using measurement of oxidative stress (OS) with ThermoChemiLuminescence technology. Our core activity is developing non-invasive, rapid assays that quantify \os and related biomarkers in biological fluids. This platform enables early detection, patient stratification, treatment monitoring across multiple clinical domains. We invest in R&D, translating scientific insights into clinical solutions | We are looking for US partners who may use our technology and assist in planning and performing the right studies to prove the efficay of our solution. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Robert Matthews | NudgeWorX | drrobmatthews@gmail.com | San Diego, CA | Specializing in frugally engineered, high-reliability ultrasound systems, we have built low-cost platforms for multiple groups, several advancing to commercial deployment. We focus on extracting high-quality acoustic and physiologic data from minimal-cost hardware through strong system architecture and robust analog design. By combining low-cost Doppler, pulse-echo, and multimodal sensing with advanced AI, we aim to expand access to powerful diagnostic tools. | We are seeking AI experts to collaborate with us on translating these systems into practical, impactful products. Ideal partners will help fuse our resilient, scalable hardware with intelligent software to deliver actionable maternal–fetal insights at global scale. | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Jana Kainerstorfer | Carnegie Mellon University | jkainers@andrew.cmu.edu | Pittsburgh, PA | We develop diffuse optical instruments for measuring tissue perfusion. We have worked on transabdominal fetal pulse oximetry for several years and have recently shown quantitative results from sheep. | Clinical collaboration | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Anton Geiler | LLG Associates | ageiler@llga.us | Boston, MA | Room temperature unshielded quantum sensors | Clinical expertise, go to market partner | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Michele Darrow | Rosalind Franklin Institute | michele.darrow@rfi.ac.uk | Harwell Campus, United Kingdom | Multi-modal, multi-scale imaging and image analysis followed by computational simulation of oxygen transport during pregnancy | clinical validation partners, co-development partners | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Xia Zhou | Columbia University | xia@cs.columbia.edu | New York, NY | We study noninvasive physiological sensing with non-adhesive textile/fabric sensors. We follow a methodology of hardware-software co-design, which integrates novel hardware designs with AI and machine learning techniques to refine signal quality and achieve reliable inference of various physiological signals. As an example, our prior work has developed a fabric necklace for continuous, noninvasive monitoring of Kangaroo Mother Care and newborn's vital signs: https://mobilex.cs.columbia.edu/joey/ | Clinical collaborators | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Sriraam Natarajan | University of Texas at Dallas | Sriraam.Natarajan@utdallas.edu | Dallas, TX | Development of machine learning, casual learning and generative learning models for adverse pregnancy outcomes | Deliverables of developed algorithms | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Mohammad Moghimi | Wake Forest University School of Medicine | smoghimi@wakehealth.edu | Winston Salem, NC | Dr. Moghimi’s lab designs, fabricates, and characterizes micro-sensing systems, flexible bioelectronics, and wearable devices for monitoring patient vital signs and detecting physiological abnormalities. Our group recently developed a wearable patch capable of identifying abnormalities associated with skin cancer. We also conduct clinical studies to evaluate the safety and efficacy of medical devices and wearable health technologies. | We are interested in collaborating on the development of new sensing modalities and advanced monitoring technologies for both maternal and fetal health. We are also interested in collaborating on clinical trials involving sensors and devices. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Roger Young | PreTeL, Inc | ryoung@pretelhealth.com | Portland, OR | Oxytocin is used to enhance uterine contractions in 2 M US women annually, but a means to directly measure the stimulatory effects is currently lacking. Overstimulation results in fetal hypoxia and Cesarean delivery; Under-stimulation results in long labor and infection. Using patented directional EMG sensors, PreTeL quantifies the current amount of uterine stimulation as the strong uterine contractions of labor evolve. This information allows precise dosing of oxytocin and fewer complications. | PreTeL currently has excellent medical expertise in obstetrics and recording EMG. We are looking for partners with A) deep expertise in signal processing and real time display; B) patient friendly and inexpensive materials for constructing EMG sensors; C) new methods to evaluate the fetal status with specificity better than fetal heart rate alone. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Neil Anderson | Saiiv Monitoring Solutions | neil@saiiv.com | Sydney, New South Wales, Australia | We have developed SMARTNATAL, a non-invasive multimodal maternal–fetal monitoring solution that combines electrical, acoustic and biomechanical sensing with advanced signal processing. Our platform provides an end-to-end ML pipeline integrating sensor data, clinical history and physiological inputs to generate real-time risk scores, decision support and longitudinal prenatal, intrapartum and postnatal tracking. | We seek strategic partners with complementary maternal–fetal sensing technologies that can integrate with our platform, and U.S. clinical sites interested in collaborative co-design and workflow testing. Ideal partners contribute to hardware integration and UX customisation for U.S. labor and delivery settings. Clinical trials will be coordinated through our CRO partner, and we can align our clinical and regulatory strategy with large industry collaborators. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Colleen Kincaid | Arbor Research LLC | colleen.kincaid@arborresearch.org | Ann Arbor, MI | Arbor Research is a national leader in data-driven healthcare improvement, specializing in clinical research, predictive analytics, and multi-site quality initiatives. We advance biomarker validation, risk modeling, and point-of-care diagnostics with strong regulatory and data systems. In maternal health, we support the Obstetrics Initiative CQI with statewide data collection, analytics, and reporting to improve outcomes for all after childbirth. | Arbor Research is a national leader in data-driven healthcare improvement, specializing in clinical research, predictive analytics, and multi-site quality initiatives. We advance biomarker validation, risk modeling, and point-of-care diagnostics with strong regulatory and data systems. We support clinical quality initiatives in maternal health via data collection and implementation to improve outcomes and reduce unnecessary interventions. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Katie Kugler | Vivid BioInnovations | KKugler@vivid-bio.com | San Francisco, CA | Vivid BioInnovations develops rapid, ultrasensitive nucleic-acid diagnostics using breakthrough droplet-microfluidic and digital-assay technologies. Our platforms enable point-of-care quantification of DNA/RNA biomarkers, delivering innovative, integrative, and impactful insights. Current work spans HIV viral-load testing and multi-omic single-cell analysis; we now aim to extend this proven architecture to fetal–placental risk markers for intrapartum hypoxia prediction. | We seek partners with: (1) L&D clinical sites serving Medicaid patients (rural hospital, urban academic center, or birthing center) with IRB/sample-collection capacity; (2) MFM or OB expertise for biomarker selection, trial design, and workflow integration; (3) bioethics and health-equity experience; (4) IVD regulatory expertise (510(k)/De Novo, CLIA). We bring a validated digital NA POC platform—ideal complements are clinical access, regulatory strategy, and obstetric domain knowledge. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Cassandra Adams | PrῑmSphera | cadams@primsphera.tech | South Bend, IN | PrīmSphera is a revolutionary non-contact sensor technology company pioneering break-through solutions to improve effective decision making and solve real-world challenges. Our flagship platform leverages patented RF PMD algorithms to measure changes in fluid balance, heart rate, and respiratory rate to deliver actionable insights that enable early intervention. We continue to expand sensor capabilities to deliver a comprehensive suite of non-contact clinical insights. | The pre-production version of our non-contact sensor has demonstrated measuring heart rate and respiratory rate with a comparable and superior (in the case of respiratory rate) accuracy to present wearable (PPG based) technologies. We are seeking teaming partners for the MOCS program with strengths in clinical validation, product definition and validation, ISO-13485–aligned scaling and manufacturing, digital health ecosystem integration, and operational collaboration with healthcare systems. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Arjan Durresi | Indiana University Indianapolis | adurresi@iu.edu | Indianapolis, IN | Applying Causal AI in medical fields. | Looking for partners to explore causal AI in these medical problems. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Richard Leuchter | UCLA (David Geffen School of Medicine) | rleuchter@mednet.ucla.edu | Los Angeles, CA | Advanced logistics to deliver urgent care equipment. Deep learning models. | Industry partners with fetal monitoring devices | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Dave Esra | BobiHealth | dave@bobihealth.com | San Antonio, TX; Denver, CO; and Washington DC area, TX | BobiHealth has developed an accessible maternal health data collection app that runs on a user’s own device and integrates with OTS and clinical wearables and sensors to monitor comprehensive biometrics and mental health indicators. Our research advances AI-driven risk prediction, real-time alerts, and equitable care solutions for high-risk and underserved pregnancy populations. | We seek partners in maternal–fetal sensors, diagnostics, OB clinical trials, and regulatory strategy. Ideal collaborators include hardware and wearable developers, biomarker/POC testing teams, and hospital systems to validate integrated monitoring solutions for high-risk and underserved pregnancy populations. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Talia Eisenberg | Beond | Talia@beond.us | San Francisco and Cancún, México, CA | Ibogaine data and research | To learn more and support | Collaborator, Collaborator |
| Jane Corteville | Case Western Reserve University | jec20@case.edu | Cleveland, OH | The use of combined ultrasound and photonics for direct fetal assessment | Collaboration with industry, AI and ultrasound tissue perfusion expertise | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Marcel Botha | 10XBeta | subscriptions@10xbeta.com | USA, NY | Next-generation obstetric connected devices use edge computing to analyze signals on the device itself, keeping sensitive data local and reducing exposure risk. Privacy-preserving models, secure sensor networks, and intuitive interfaces bring clinical insight into the home while limiting data transmission. This design-led approach supports safer pregnancies in urban and rural health deserts by delivering timely monitoring without sacrificing trust or privacy. | We seek a partner with practical expertise in privacy-preserving machine learning/AI systems for sensitive maternal and fetal data. This partner should be able to implement differential privacy or federated approaches in production environments, build on-device models that minimize exposure risk, and create secure data pipelines that integrate directly with obstetric sensors. Experience with cybersecurity, threat modeling, and real-world testing using noisy physiological signals is a plus. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Tyona Pike | F&I Foresight Initiatives | Pikesforesightinitiatives@gmail.com | Cookeville, TN | We actively support research and innovation efforts through case management, patient advocacy, and care coordination. Our organization is open to collaboration that advances maternal health outcomes, patient engagement, and data-driven service delivery in alignment with health research and development goals. | We are open to conversations with potential teaming partners, including but not limited to healthcare researchers, technology developers, maternal health innovators, academic institutions, and clinical organizations. We seek collaborators dedicated to advancing safe, data-driven, and patient-centered care to improve maternal and infant health outcomes. | Collaborator |
| Gari Clifford | Emory University | gari@ieee.org | Atlanta, GA | Focusing on AI-driven systems for fetal & maternal monitoring and modeling, integrating low-cost sensors, Doppler, & ECG to predict complications during labor. Our work uses deep learning for real-time maternal-fetal signal analysis, multimodal data fusion, & edge-compute mHealth platforms to support clinicians and improve outcomes. With applications in fetal development, hypoxia, & fetal activity, from the 2nd trimester onwards, we have extensive experience in translation & regulation. | We are looking for partners that can provide near-infrared spectroscopy of the placenta for abdominal monitoring fetal oxygenation, and expertise in ultrasound sensor development, miniaturization of a reduced-lead noninvasive fetal ECG monitor for portable wireless use. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Dr. Hadas Ziso | EndoCure Ltd | hadas@endocure.tech | Haifa | EndoCure is building a proprietary robotic ultrasound imaging platform, Revealan™, that redefines diagnostic imaging for complex conditions like endometriosis and cancer. Unlike conventional ultrasound, which is highly operator-dependent, Revealan™ delivers standardized, reproducible 3D imaging with 10x the density of MRI, enabling more accurate and reliable diagnosis. | We offer using Revealan™, our robotic ultrasound imaging platform, which seamlessly integrates with any off-the-shelf ultrasound device to enable operator-agnostic, automated, AI-enabled, high-resolution 3D imaging. The robotic scan output is a series of standardized medical images with a density 10 times higher than that of an MRI. With Revealan™, we allow early detection and reliable follow-ups of small findings. We will be happy to collaborate in relevant clinical studies. | Collaborator, Collaborator |
| Robert Matthews | NudgeWorX | drrobmatthews@gmail.com | San Diego, CA | Specializing in frugally engineered, high-reliability ultrasound systems, we have designed and built low-cost platforms for multiple groups, several of which have progressed through commercialization and market deployment. Our work focuses on achieving high-quality acoustic and physiologic data from minimal-cost hardware through thoughtful system architecture, robust analog front-end design, and manufacturable engineering. | We are seeking AI experts to collaborate with us on translating these systems into practical, impactful products. Ideal partners will help fuse our resilient, scalable hardware with intelligent software to deliver actionable maternal–fetal insights at global scale. | Collaborator |
| Sameer Sonkusale | Tufts University | sameer.sonkusale@tufts.edu | Boston, MA | Biomedical Devices, Wearables, Chemical and Biological Sensors, Point of care diagnostics, Microelectronics, Integrated Systems | Clinical partners, AI/ML Expertise | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Nada Hanafi | MedTech Strategy Advisors, LLC | nada@medtechstrat.com | Santa Barbara, CA | MedTech Strategic Partners: Concept to Commercialization With 50+ years combined MedTech experience, we guide medical device innovators through regulatory strategy, clinical evidence generation, quality systems, and product development. From FDA submissions to ISO 13485 compliance and clinical trials, we accelerate your path to market while ensuring patient safety and commercial success. Your trusted partner in transforming breakthrough ideas into life-changing healthcare solutions. | Innovators, founders and medical device companies working in the space requiring strategic advice, regulatory pathway, product development and evidence generation support and guidance. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Jose Cortes-Briones | Wavelet Medical Inc | jose.briones@yale.edu | Brooklyn, NY | Our work centers on the noninvasive reconstruction of fetal EEG and ECG from signals collected by sensors attached to the maternal abdomen. Changes in fetal EEG provide an early and sensitive marker of hypoxia, and combining these signals with information extracted from fetal ECG as well as from maternal signals such as uterine contractions, respiration, and ECG will enable detection of emerging fetal hypoxia with an accuracy and precision not achievable with current monitoring methods. | We are looking for collaborators with expertise in multimodal sensor design, hardware and firmware development, signal processing, real-time analytics, EMR integration, and FDA device regulatory strategy. We are also interested in partners with experience in human-subjects research, clinical usability testing, and design controls relevant to intrapartum monitoring systems. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, Collaborator |
| Yalcin Yamaner | Clearsens, Inc. | yalcin@clearsens.com | Raleigh, NC | Wearable ultrasound | Clearsens, Inc. advances next-generation ultrasound imaging through chip-scale CMUT arrays, flexible transducer platforms, and high-resolution wearable systems. Our research focuses on wideband array design, low-power electronics, and real-time imaging algorithms to enable continuous monitoring for biomedical applications. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Jun Gregg | Grant Engine | jun@grantengine.com | New York, NY | Grant Engine is a full-service non-dilutive funding consultancy with 40+ PhDs and a win rate 2–4x the national average, securing over $1B in the past 9 years. We have deep women’s health expertise in point-of-care diagnostics, intrapartum monitoring, and data-driven maternal care. We optimize consortia, engage stakeholders, craft proposals aligned with agency priorities, and support post-award compliance, tailoring every engagement to agency and client needs. | As an experienced player in the non-dilutive funding space in our tenth year, we are seeking to join a team as a key partner in support of meeting MOCS programs goals through strategic collaboration, proposal development, and formation of consortia. Our prime directive is to meet the goals of MOCS TA1 and TA2 by aligning our capabilities with those of strong performers so that together we realize the aims of dramatically improving maternity care across the labor and delivery continuum. | Collaborator |
| Hannah Mazur | SRI International | hannah.mazur@sri.com | Menlo Park, CA | SRI brings predictive analytics combining causal analysis of multi-modal time series data for key factor identification and counterfactual treatment evaluation; multi-scale modeling for personalized predictions; and enhanced model confidence and usability through calibration, uncertainty estimation, interpretability, and drift detection. Advanced hardware and sensing, including novel optical, arrayed, and electromagnetic sensor development and integration into wearable patches and textiles. | SRI seeks partners who complement our technical capabilities with clinical access, regulatory expertise, manufacturing scale-up, and commercialization pathways. We aim to collaborate with clinical groups for data collection, user feedback, and workflow validation; with organizations skilled in medical device productization, sensor manufacturing, wearable integration, and FDA strategy; with partners who can drive health-economic analysis, reimbursement planning, and commercial adoption at scale. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Dave Esra | BobiHealth | dave@bobihealth.com | BobiHealth has members located in San Antonio, TX; the Washington DC area; and Denver, CO., TX | BobiHealth has developed an accessible maternal health data collection app that runs on a user’s own device and integrates with OTS and clinical wearables and sensors to monitor comprehensive biometrics and mental health indicators. Our research advances AI-driven risk prediction, real-time alerts, and equitable care solutions for high-risk and underserved pregnancy populations. | We seek partners in maternal–fetal sensors, diagnostics, OB clinical trials, and regulatory strategy. Ideal collaborators include hardware and wearable developers, biomarker/POC testing teams, and hospital systems to validate integrated monitoring solutions for high-risk and underserved pregnancy populations. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Yalcin Yamaner | Clearsens, Inc. | yalcin@clearsens.com | Raleigh, NC | Clearsens, Inc. advances next-generation ultrasound imaging through chip-scale CMUT arrays, flexible transducer platforms, and high-resolution wearable systems. Our research focuses on wideband array design, low-power electronics, and real-time imaging algorithms to enable continuous monitoring for biomedical applications. | We seek teaming partners with strong AI and machine-learning capabilities, particularly those experienced in medical imaging, physiological monitoring, and clinical decision support. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Spencer Lynn | Charles River Analytics | slynn@cra.com | Cambridge, MA | We apply a broad AI/ML and engineering portfolio. We develop classical and deep learning approaches for prediction, anomaly detection, perception, classification, and sensor fusion with deep reinforcement learning and meta-RL for adaptive control in complex environments. Probabilistic programming and causal models support principled decision-making under risk. Neuro-symbolic AI, semantic NLP pipelines, LLM fine tuning, and human-centered AI enable robust, transparent human–machine teams. | We bring AI/ML and engineering expertise; an extensive background leading large multi-partner programs with ARPA-H, DARPA, IARPA, and others; and biomedical research experience. We seek to join or lead a team that includes biomedical engineers specializing in non-invasive sensing of fetal oxygenation status, maternal–fetal medicine clinician researchers, and regulatory and health IT experts to ensure HIPAA/FDA compliance and safety. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Ryan Callahan | Prova Health | ryan.callahan@provahealth.com | Miami, FL | We have experience specifically in obstetric diagnostic technology, supporting a variety of organizations (academic labs, start-ups, and enterprises) to successfully commercialize innovative products and services. We are familiar with both core scientific challenges in improving obstetric care as well as health system realities that have limited the impact of the previous generation of technologies. We previously worked with a similar effort led by a different ARPA-like organization. | We are looking to partner with teams who have a strong technical and clinical background and who want to de-risk the scaled adoption of their technology into the healthcare system. We can help with reimbursement strategy, ideal customer profiles, go-to-market plans, sales forecasting, strategic exit options, competitive analysis, clinical workflow, simulation-based feasibility testing, and adjacent activities. | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Mohammad Moghimi | Wake Forest University School of Medicine | smoghimi@wakehealth.edu | Winston Salem, NC | Dr. Moghimi’s lab designs, fabricates, and characterizes micro-sensing systems, flexible bioelectronics, and wearable devices for monitoring patient vital signs and detecting physiological abnormalities. Our group recently developed a wearable patch capable of identifying abnormalities associated with skin cancer. We also conduct clinical studies to evaluate the safety and efficacy of medical devices and wearable health technologies. | We are interested in collaborating on development of new sensing modalities and advanced monitoring technologies for maternal and fetal health. We are also interested in collaborating on clinical trials involving sensors and devices. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Mrignayani Kotecha | O2M Technologies, LLC | mkotecha@oxygenimaging.com | Chicago, IL | Oxygen Imaging: we are developing instrumentation, contrast agent and methodology for imaging partial oxygen pressure (pO2) maps in vitro and in vivo using electron paramagnetic resonance (EPROI). EPROI is similar to MRI, as it uses a very low static magnetic field (9-25 mT), magnetic field gradients, and rf pulses to generate pO2 maps. What sets EPROI apart is its ability to offer direct, quantitative, and real time pO2 maps without relying on indirect metabolic markers. EPROI uses tritylOXO71. | We are looking for complementary expertise and organization who will be interested in assisting us to develop pO2 imaging technology for fetal and placenta pO2 imaging in NHPs and in humans. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Jeeun Kang | Johns Hopkins University | kangj@jhmi.edu | Baltimore, MD | Our multi-disciplinary team at Johns Hopkins University (medical instrumentation, ultrasound, biophotonics, medical image analysis, artificial intelligence, and electronic/computer engineering, neurovascular physiology, obstetrics & gynecology) focuses on developing a wearable ultrasound and photoacoustic device for stratification and monitoring of fetal health and labor progress over the peripartum period. | Exploring teaming partners for productization, commercialization, and clinical validation of our engineering solution. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Katie Kugler | Vivid BioInnovations | KKugler@vivid-bio.com | San Francisco, CA | Vivid BioInnovations develops rapid, ultrasensitive nucleic-acid diagnostics using breakthrough droplet-microfluidic and digital-assay technologies. Our platforms enable point-of-care quantification of DNA/RNA biomarkers, delivering innovative, integrative, and impactful insights. Current work spans HIV viral-load testing and multi-omic single-cell analysis; we now aim to extend this proven architecture to fetal–placental risk markers for intrapartum hypoxia prediction. | We seek partners with: (1) L&D clinical sites serving Medicaid patients (rural hospital, urban academic center, or birthing center) with IRB/sample-collection capacity; (2) MFM or OB expertise for biomarker selection, trial design, and workflow integration; (3) bioethics and health-equity experience; (4) IVD regulatory expertise (510(k)/De Novo, CLIA). We bring a validated digital NA POC platform—ideal complements are clinical access, regulatory strategy, and obstetric domain knowledge. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Hongzhang He | Captis Diagnostics | simonhe@captisdx.com | Pittsburgh, PA | Captis Diagnostics provides a magnetic bead–based technology for isolating extracellular vesicles from blood samples. This platform enables multi-omics analyses—including genomics, transcriptomics, and proteomics—to support comprehensive patient outcome assessment. | We can look for sensor developer, and AI/ML, and clinical partners. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Deborah Fox | University of Technology Sydney | deborah.fox@uts.edu.au | Sydney, Australia | Our expertise is investigating the impact of innovative fetal monitoring technologies upon pregnant and birthing women (and people), the clinicians caring for them and the health systems in which they are situated. We partner with health services, consumers, engineers, innovators and clinicians at the design, implementation and/or evaluation stages of device development. Peer reviewed publications are available on request. | We are seeking US/global collaboration on midwifery/obstetric/maternity care research and implementation projects in the field of fetal monitoring, telehealth and/or telemonitoring. We can provide a focus on the user experience and clinical translation. | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Tauhidur Rahman | University of California San Diego | trahman@ucsd.edu | San Diego, CA | Tauhidur Rahman is an Assistant Professor at the HDSI and CSE at the UC San Diego. His research focuses on designing novel mobile and ubiquitous sensing technologies using on-body and off-body sensors to capture fine-grained physiological and behavioral signals. He develops generative AI-enabled digital twin architectures that translate these signals into meaningful biological and behavioral insights, enabling trend forecasting, risk assessment, and just-in-time interventions. | I am looking to partner up with hardware/device companies that offer wearable solutions. We can provide the state of the art foundation wearable models and end-to-end data pipeline. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Sophie Beckman | Cimit | sbeckman3@mgh.harvard.edu | Boston, MA | Cimit is a leader in health innovation with 25 years of experience advancing groundbreaking solutions to complex health challenges. We use our hands-on approach, proven process, custom tools, and global experts to accelerate innovative ideas toward commercialization. Recently, Cimit led the NIH RADx Maternal Health and Fetal Monitoring challenges, further strengthening our expertise in evaluating, derisking, accelerating, and deploying targeted maternal, fetal, and reproductive health solutions. | Cimit seeks collaborative partners that will benefit from complex project management, data integration, engineering, product-market fit, regulatory, and commercialization support. We offer expertise in early-stage evaluation, derisking, innovation and solicitation management, and consortium coordination. Partners can leverage our tailored infrastructure, tools, resources, expert network, and streamlined methodologies to advance their integrated obstetrics solutions. | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Wilson Adams | QUEL Imaging | wilson@quelimaging.com | White River Junction, VT | QUEL Imaging develops and manufactures optical tissue phantoms for biomedical sensing applications. Our phantom technologies and optical simulation capabilities help cut cycle times by reducing animal and human testing needs in early development. Backed by decades of combined tissue optics experience, we strive to help bring optical sensing devices to market quickly, safely, and efficiently with world-class biomedical optical systems expertise. | We are looking to collaborate on optical sensing device proposals to bring ideas through prototyping quickly. Our team 3D prints and casts complex, multi-material phantoms for NIR spectroscopy, PPG, fluorescence sensing systems, and more. Additionally, we have extensive in-house photon transport computational simulation infrastructure and reference-grade analytical spectroscopy equipment for characterizing material optical properties. | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Ashley Copenhaver | Netrias | acopenhaver@netrias.com | Annapolis, MD | Netrias focuses on two key areas powered primarily by machine learning/artificial intelligence: 1) predictive modeling to identify and monitor biomarkers/health states, and 2) large-language model-driven harmonization technology to integrate and standardize datasets across research groups/experimenters/modalities. We have experience working with various government agencies (i.e. DARPA, NCI, NIAAA, DTRA, etc). We have recent/current work in area (1) with DARPA, and in area (2) with NCI and DTRA. | We are looking for strong sensor development and hardware (monitor) development collaborators for TA2. Additionally, we are searching for strong teaming partners on the TA1 side including clinical partners and hardware or sensor developers to collect biomarker data. | Collaborator, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Kathryn Zealand | Project Stardust | kathryn.zealand@gmail.com | San Francisco, CA | Commercialisation of non-invasive monitoring for fetal status in final trimester, including wearable ultrasound | Clinical and development partners | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | My focus is on the development of microneedle devices for electrochemical detection of a variety of biologically relevant molecules as well as the use of artificial intelligence to enhance the usability of biosensor data. | I am looking for teaming partners with complementary expertise to address the project requirements, including handling of sensor data in accordance with project requirements. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Mrignayani Kotecha | O2M Technologies, LLC | mkotecha@oxygenimaging.com | Chicago, IL | Development of oxygen imaging technologies for diagnosis and treatment of various pathologies. | Subject expertise in obstetrics care, fetus development, etc. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Salim Malakouti | NOMA AI INC. | salim@noma.ai | Pittsburgh, PA | Developing multimodal AI for proactive monitoring of risk of medical complications | Collaborators with complimentary expertise and technology | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Robert Rohling | University of British Columbia | rohling@ece.ubc.ca | Vancouver, Canada | Our current focus is ultrasound of the placenta. My lab at UBC (Robert Rohling) has worked with UNCC (Farah Deeba) to develop a novel quantitative ultrasound tool to detect the risk of hypoxia by analyzing the placenta. This novel tool was developed under the Wellcome Leap In Utero program with n=246 subjects in Vancouver, Canada and n=1463 at sites in USA, UK, Uganda. The study was completed in 2025 and we are now drafting the journal publication. The results are very promising. | We are looking for more clinical partners to perform studies. We are also looking for experts in Doppler and perfusion ultrasound to bring complementary measures of placental function. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Ernie Graham | Johns Hopkins University School of Medicine | egraham5@jhmi.edu | Baltimore, MD | Photoacoustic imaging of fetal brain and placenta, Machine learning | More expertise in photoacoustic imaging and machine learning | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Kerem Pekkan | The Ohio State University | kpekkan@ku.edu.tr | Columbus, OH | My lab develops clinically validated digital twins of the fetal cardiovascular system, covering the pre-term to post-partum period. Here are some foundational papers for this work: https://pubmed.ncbi.nlm.nih.gov/31011431/ https://pubmed.ncbi.nlm.nih.gov/25773588/ | I aim to integrate our simulation expertise with emerging instrumentation, hardware, and new fetal imaging modalities, including time-resolved 3D fetal motion analysis, supported by AI/ML tools. My lab also develops and tests fetal-targeted sensors, building on Nationwide Children’s strong foundation in fetal animal models, imaging, and interventions for congenital heart disease. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, Collaborator |
| Julia Komissarchik | Glendor, Inc | julia@glendor.com | Draper, UT | Glendor is on a mission to safeguard patient privacy while accelerating medical innovation. With its automated, at-source, at-scale de-identification technology, Glendor enables healthcare data custodians to share and aggregate multimodal medical data —advancing clinical research, AI model training, and real-world evidence generation without compromising patients’ privacy. Glendor’s customers include government, hospitals, lab networks, pharmaceuticals, AI companies, and medical data lakes. | We provide PHI deidentification software solution. We are looking for partners who would like to deidentify their and their contributors' data on their sites (on premises or in the cloud). Use Case 1: deidentification of data before it is shared, to ensure that there are no HIPAA violations Use Case 2: deidentification of data before it enters the exchange or partner site, to ensure that there are no HIPAA violations PHI Sanitizer can be used standalone or to augment existing workflow. | Collaborator |
| Jyotnsa Batra | Bond University | jbatra@bond.edu.au | GoldCoast Australia | Non-coding RNA, genomics, miRNA, polygenic risk scores, hypoxia models | we look for collaborating and imparting our expertise in this filed which touches many lives. | Collaborator, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Sihong Wang | The University of Chicago | sihongwang@uchicago.edu | Chicago, IL | Wearable and implantable bioelectronic devices | Obstetrics doctor, medical data analysis, machine learning | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Jay Ward | MindChild Medical, Inc. | jay.ward@mindchild.com | North Andover, MA | MindChild Medical is dedicated to improving outcomes for mothers and their babies. We manufacture an FDA-cleared, maternal-fetal intrapartum monitor based on non-invasive fetal ECG technology, with expertise in ultra-low-noise signal acquisition, real-time signal processing, and ISO certified manufacturing. We obtained patents on the fetal ECG extraction algorithm and multi-sensor arrays. We were chosen by The Gates Foundation for our fetal ECG capabilities, recording 8k births in 3rd world | MindChild Medical seeks partners with expertise in AI diagnostic development on maternal ECG, uterine activity, fetal ECG, and new data from sensors added to the platform to achieve TA2’s objective. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Paul Christie | TACHMED | pceo@tachmed.com | London | Tachmed is developing a group of electrochemical biosensors for point of care use including enzymatic immunoassays, ion sensors, reader hardware, data integration and AI-enabled analysis pipelines. We have established capability in rapid biochemical testing using ultra low volume samples, electro-chemical assay optimisation and regulatory-aligned validation planning. We also have an active programme investigating cardiovascular, renal and inflammatory biomarkers, maternal and perinatal health. | Tachmed needs strong clinical partners in obstetrics and maternal foetal medicine and intra-partum monitoring. To provide clinical insights to refine use cases, workflow optimisation and definitions of foetal oxygenation risk. seeking patterns in maternal physiology, placental biology and biomarker validation. We are also seeking partners in human factors engineering, clinic translation and biomedical data science. | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |
| Xiaoyue Ni | Duke University | nixiaoyue@gmail.com | Durham, NC | We focus on the development of wearable, flexible ultrasound and photoacoustic (PA) imaging systems for continuous, non-invasive physiological monitoring. Our technology combines: 1) a smart, skin-adaptive ultrasound array that maintains robust 4D imaging fidelity during patient motion, and 2) integrated PA modalities to directly measure tissue oxygen saturation. We have capabilities in flexible sensor hardware, PA physics, and urban academic clinical validation (Duke Ob/GYN). | We are looking for complementary partners: 1) clinical validation sites (rural hospitals and community birthing centers) for testing in diverse delivery settings, 2) AI/ML expert to develop the "suggested next best step", 3) a malpractice attorney specializing in obstetrics and a clinical bioethicist to address the medicolegal and ethical implications of novel data, 4) system integrators: partners with experience in wireless data transmission and EMR integration. | TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia, TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia |
| Tasnim khan | Raya Health | tasnim@findraya.com | San Francisio, CA | Raya Health- not doing current research. AI powered maternal health organization- for profit with doulas/wraparound services serving california right now | We can partner with the developers of the technology to test these in the field with patients | Collaborator, Collaborator |
| Naser Darwish | Detectpath | naser.darwish@gmail.com | Berwyn, IL | DetectPath develops all-optical ultrasound and photoacoustic fiber-based sensing technologies for real-time, in-tissue monitoring of oxygenation, perfusion, and tissue boundaries. Working with UMass Lowell on fiber-optic engineering and with clinicians at MGH, we design minimally invasive optical probes that eliminate external ultrasound hardware for continuous monitoring in high-risk settings, including intrapartum fetal hypoxia. | We seek partners in maternal–fetal medicine, obstetrics, and intrapartum monitoring, as well as collaborators with expertise in biophotonics, optical engineering, advanced signal processing, and data-driven analysis. Ideal teams include clinicians experienced in labor-and-delivery studies, regulatory specialists for maternal–fetal devices, and groups that can support prototype testing with our collaborators at UML and MGH | TA1: Development of a Point of Care Test for Stratification by Risk for Intrapartum Fetal Hypoxia, TA2: Development of a Novel Intrapartum Fetal Monitor for Objective Assessment of the Fetus with Suggested Next Best Step for Treatment of Hypoxia |